US EditionPublished • loading... • Updated
Wilmington biotech firm advances synthetic CBD drug to Phase I trials
Summary by wilmingtonbiz.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Wilmington biotech firm advances synthetic CBD drug to Phase I trials
Wilmington-based Isosceles Pharmaceuticals will begin Phase I human trials of IPI201, a laboratory-created cannabidiol drug targeting inflammation-related pain as a non-opioid alternative. Phase I testing with healthy volunteers is expected to start by April, marking the company’s transition from preclinical development toward potential commercialization.
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
